FIELD: biotechnology.
SUBSTANCE: recombinant production of an antibody or an isolated antibody fragment that binds to canine IL31, and can be used in veterinary medicine for the treatment of an IL31-induced condition.
EFFECT: obtaining an antibody or an isolated antibody fragment capable of binding to IL31 and reducing the signaling function of IL31 in cells.
53 cl, 13 dwg, 5 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF Fc-REGION WITH ALTERED BINDING TO NEONATAL Fc-RECEPTOR (FcRn) FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2830231C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| MODIFIED ANTIBODY CONSTANT REGION | 2021 |
|
RU2797273C2 |
